RSS   Newsletter   Contact   Advertise with us

uniQure appoints two to board of directors

Staff Writer | Amsterdam, The Netherlands | June 14, 2018
UniqureUniqure, a human gene therapy company, announced the appointment of Robert Gut and David Meek to its board of directors.
Robert Gut has nearly 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas.

For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc., where he headed the company’s U.S. Biopharm Medical organization with leading products in hemophilia, endocrinology and women’s health.

Over past years, Dr. Gut’s contributions have helped achieve six FDA product approvals and three new product indications.

Dr. Gut has supported the launch of nine new products, overseeing medical activities including medical science liaison team building and health economics and outcomes research.

He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research.

Dr. Gut was appointed the Chief Medical Officer of Versartis, Inc. in September 2017 and received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland.

He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.

David Meek has over 25 years of experience in the pharmaceutical industry where he has held various global executive positions in major pharmaceutical and biotechnology companies.

Mr. Meek was appointed CEO of Ipsen in July 2016 and also serves on its Board of Directors.

Prior to this, he was Executive Vice-President and President of the oncology division of Baxalta.

Mr. Meek also served as Chief Commercial Officer for Endocyte, a biotech focused on oncology, and spent 8 years at Novartis as a global franchise head, CEO of Novartis Canada, and region head of oncology for northern, central and Eastern Europe.

Earlier in his career, he spent 14 years at Johnson & Johnson and Janssen Pharmaceutica, where he held a variety of senior U.S. sales and marketing positions.

Mr. Meek holds a B.A. in Management from the University of Cincinnati.

 LATEST MOVES FROM The Netherlands